AIDSVu Releases New Data Showing Significant Inequities in PrEP Use Among Black and Hispanic Americans
July 29, 2022 12:30 ET | AIDSVu
ATLANTA, July 29, 2022 (GLOBE NEWSWIRE) -- Today, AIDSVu released the first-ever publicly available state-level PrEP use data and maps by race/ethnicity from 2012 to 2021, showing that while PrEP...
Exavir Therapeutics announces publication of preclinical data for ultra-long-acting dolutegravir prodrug XVIR-120
June 09, 2022 07:00 ET | Exavir Therapeutics
Ultra-long-acting plasma pharmacokinetics and biodistribution to tissues of interest demonstrated in three species Injections were well tolerated with no adverse findings in preliminary toxicology...
Exavir Therapeutics Completes $4M Seed Financing from Key Investors
May 23, 2022 07:00 ET | Exavir Therapeutics
NEW YORK and OMAHA, Neb., May 23, 2022 (GLOBE NEWSWIRE) -- Exavir Therapeutics, a company dedicated to transforming the lives of people living with or at risk of acquiring HIV, today announced that...
Global and Historical Trends - HIV Epidemiology Forecasts to 2029
February 22, 2022 05:53 ET | Research and Markets
Dublin, Feb. 22, 2022 (GLOBE NEWSWIRE) -- The "Human Immunodeficiency Virus (HIV) - Epidemiology Forecast to 2029" report has been added to's offering. The total prevalent...
Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV
September 16, 2021 07:30 ET | Exavir Therapeutics
With a single administration, XVIR-210, a nano-formulated prodrug of tenofovir, provided drug levels sufficient for chronic HBV treatment, HIV treatment, and HIV prophylaxis for over two months in...
Exavir Therapeutics announces the publication of preclinical data for the ultra-long-acting integrase inhibitor XVIR-110 in Nature Communications, affirming its unique pharmacokinetic profile and potential as a best-in-class yearly antiretroviral
June 08, 2021 07:00 ET | Exavir Therapeutics
With a single administration, XVIR-110, a nano-formulated prodrug integrase inhibitor, provided year-long plasma drug levels sufficient for HIV treatment and prophylaxis in animal models Studies...
APLA Health & Wellness to Open New Long Beach Health Center in January 2016
September 29, 2015 14:23 ET | AIDS Project Los Angeles
LONG BEACH, Calif., Sept. 29, 2015 (GLOBE NEWSWIRE) -- APLA Health & Wellness (APLAHW) is proud to announce that we have been funded to open a new federally qualified health center in Long Beach...
Patient Advocate Foundation logo
Co-Pay Relief Program Unveils New Financial Assistance for Patients with HIV, AIDS or Those Being Treated to Prevent the HIV Virus
September 28, 2015 08:03 ET | Patient Advocate Foundation
HAMPTON, Va., Sept. 28, 2015 (GLOBE NEWSWIRE) -- The Centers for Disease Control and Prevention (CDC) estimate there are 1.2 million people living with Human Immunodeficiency Virus (HIV) in the United...